Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma × imgatuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Non-Squamous Non-Small Cell Lung Cancer 1 Neoplasms 1 Colorectal Neoplasms 1 Carcinoma 1

Interventions

Cisplatin 24 Paclitaxel 18 Carboplatin 18 Gemcitabine 12 pembrolizumab 11 Radiotherapy 9 Fluorouracil 9 Specimen Handling 8 Magnetic Resonance Spectroscopy 7 cemiplimab 6 Platinum 6 Nivolumab 6 Docetaxel 6 Cetuximab 6 1,2-diaminocyclohexaneplatinum II citrate 6 epothilone B 5 anlotinib 5 Sunitinib 5 Pemetrexed 5 Oxaliplatin 5 Everolimus 5 Drug Therapy 5 Cyclophosphamide 5 Capecitabine 5 Bevacizumab 5 durvalumab 4 Radiotherapy, Intensity-Modulated 4 Radiation 4 vosaroxin 3 sintilimab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04985825 2022-09-13

I-PACE

Centessa Pharmaceuticals plc

Phase 2 Withdrawn

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡